Kornimate/medical-research-clean huggingface dataset:
smartshoes for freezing of gait in parkinson's disease

Conditions: Parkinson Disease

Summary: this is a pilot research study aimed at evaluating whether an fda listed wearable shoe with capability to deliver vibration feedback can be safe and tolerable for patients with parkinson disease and control participants and explore whether such a feedback can be useful for treating freezing of gait (fog) in patients with parkinson disease.


Eligibility criteria:
inclusion criteria: for patients with parkinson disease: * diagnosis of pd according to the uk brain bank criteria * hoehn and yahr stages 2 to 3 during the on phase of pd medication * self-report episodes of fog based on item 1 of the nfog-q, and score of 3 on item 2, part ii for patients with parkinson disease without freezing of gait: * diagnosis of pd according to the uk brain bank criteria * hoehn and yahr stages 2 to 3 during the on phase of pd medication for all participants (pd with or without freezing, or age-matched controls): * adult age 40-80 * able to walk 10 minutes at baseline * able to provide consent * able to read and write in english at an 8th grade level. exclusion criteria: for all participants (pd with or without freezing, or age-matched controls) * moderate to severe peripheral neuropathy (based on self report or clinical exam using vibration tuning fork) which may limit ability to sense the vibratory feedback * use of orthotics incompatible with the haptic wearable shoes * severe balance deficits or daily falls at baseline * patients with dementia (moca\<18) who are not able to appropriately provide consent for the study * pregnant persons

Keywords: freezing of gait
description of fluid balance in patients with acute respiratory failure

Conditions: Respiratory Insufficiency

Summary: the specific aim of this study is to gather data on fluid balance, intravenous medication administration, electrolyte balance, and diuretic and dialysis use in patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration.

disruption of fluid balance is common in critical illness. many critical illnesses are inflammatory in nature and associated with capillary leak and swelling of tissues. while fluid administration may be necessary for the immediate resuscitation of a patient in shock, in the long term it may worsen survival and lead to complications. this is especially true in acute respiratory failure, where excess fluid can lead to a longer duration of mechanical ventilation, longer time in the icu, and a greater need for dialysis. there is also evidence that conservative fluid administration can prevent complications. fluid overload is associated with increased healthcare resource utilization and cost. much of the fluid administered to patients while in the adult icu in the united states is administered as medications via large volume infusion pumps. this is a descriptive study to gather data on fluid balance, intravenous medication administration, electrolyte balance, and diuretic and dialysis use in patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration. the information will be used to design an interventional trial of small volume medication infusion.

Eligibility criteria:
inclusion criteria: * intubation and mechanical ventilation for ≤ 7 days * an underlying condition associated with acute respiratory failure (e.g. pneumonia, ards, sepsis, asthma, copd exacerbation) * if in shock (map \< 60, fluid bolus ≥30 ml/kg or 4 l crystalloid or equivalent, vasopressors except for dopamine ≤ 5 mcg/kg/min or low-dose (≤ 0.04 iu/min) vasopressin) there should be no fluid bolus (1000 ml crystalloid or equivalent) for at least 12 hours exclusion criteria: * intubation or mechanical ventilation for \> 7 days * respiratory failure (requirement for positive pressure ventilation) in past 30 days * shock (map \< 60, fluid bolus ≥30 ml/kg or 4 l crystalloid or equivalent, vasopressors except for dopamine ≤ 5 mcg/kg/min or low-dose vasopressin) requiring fluid bolus (1000 ml crystalloid or equivalent) within past 12 hours * presence of a condition making it unlikely that the patient will be liberated from mechanical ventilation within the next 28 days (e.g. quadriplegia, end-stage lung disease, massive stroke, etc.) * prognosis from underlying condition ≤ 28 days (estimated 28 day mortality from underlying condition \>50%) * likely intention (\>50% probability) to withhold or withdraw life-supportive care within next 28 days

Keywords: fluid overload acute respiratory failure acute respiratory distress syndrome medication administration
a clinical study for validating the equivalence of bloomlife mfm-pro to clinical standard-of-care for antepartum fetal monitoring

Conditions: Fetal Monitoring

Summary: bloomlife has developed a wearable system (bloomlife mfm-pro) that can allow fetal monitoring to be conveniently performed in healthcare settings under supervision of a healthcare professional. bloomlife mfm-pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy. the purpose of this study is to validate that the bloomlife mfm-pro is equivalent to clinical standard-of-care for routine non-stress test (nst) performed at the hospital.


Eligibility criteria:
inclusion criteria: * pregnant woman ≥ 18 years old * gestational age ≥ 32 weeks and 0 days * singleton pregnancy * ability to read and understand dutch or english * willingness to participate in the study exclusion criteria: * implanted pacemaker or any other implanted electrical device * plurality higher than 1 * history of allergies to skin adhesives * contraindication to the use of the ctg
intervention module ages

Conditions: Psychosis

Summary: the ages-cm consortium aims to study the interaction between the polymorphisms of the candidate genes related with neurodevelopment, neurotransmission, brain progressive changes, cognitive functioning and stressful life events (prospective- and retrospectively assessed) and the association of the interactions with structural and functional brain measures, neuropsychological performance, biochemical and oxidative status in both in patients and controls. the investigators study aimed to examine the effectiveness of a parallel, structured, and specific psychoeducational group intervention (pe) for adolescent patients and their families by comparing it with treatment as usual).

objective: to assess the effectiveness of a structured psychoeducational group intervention for adolescents with early onset psychosis and their families. the intervention was implemented in parallel in 2 separate groups, by focusing specifically on problem solving strategies and structured psychosis-related information to manage daily life hassles associated with the disease in order to manage crises and prevent relapses. method: the investigators performed a 9-month, randomized, rater-blind clinical trial involving adolescent patients with early onset psychosis and 1 or both of their parents. the primary outcomes were number of hospitalizations, days of hospitalization, and visits to the emergency department. the secondary outcome measures were clinical variables and family environment and well being.

Eligibility criteria:
inclusion criteria: * the presence of at least one positive psychotic symptom (delusions or hallucinations) * before age 18 diagnosed by dsm-iv * aged between 14 and 19 years and lived at home with 1 or both parents, caregivers, or legal guardians. exclusion criteria: * the exclusion criteria were patient's drug abuse or dependence at the time of the intervention (drug use was not an exclusion criterion), the presence of any neurological developmental disorder or mental retardation and inability to engage in conversation or read in spanish that may interfere with the progress of group treatment.

Keywords: first episode psychosis psychoeducation group therapy
pulmonary rehabilitation in patients with fibrotic interstitial lung disease

Conditions: Fibrotic Interstitial Lung Disease

Summary: our study aims to investigate the benefits of an outpatient pulmonary rehabilitation program in a population of subjects with fibrotic interstitial lung disease. our hypothesis is that pulmonary rehabilitation will lead to improvements in quality of life, breathlessness, exercise capacity and pulmonary function in this patient population.


Eligibility criteria:
inclusion criteria: 1. restriction on pulmonary function testing (tlc \ predicted or dlco \< 80%) 2. evidence of fibrosis on high resolution computed tomography of the chest. 3. fibrosis on surgical lung biopsy if performed 4. referral for pulmonary rehabilitation exclusion criteria: 1. participation in pulmonary rehabilitation in the past 24 months 2. inability to complete 6 minute walk test or study questionnaires 3. limitations other than dyspnea (e.g. arthritis) that affect ability to participate in pulmonary rehabilitation 4. baseline 6 minute walk distance \> 400 meters 5. planned change in medication treatment for lung disease during the course of pulmonary rehabilitation 6. ejection fraction known to be \< 25% 7. contraindications to pulmonary rehabilitation (clinically unstable, uncontrolled arrhythmia or hypertension, symptomatic or uncontrolled hypotension with systolic blood pressure of \< 95, active angina, unexplained syncope or worsening dizziness, limiting orthopedic or neurological disorders, psychiatric impairment that inhibits cooperation in the program) 8. fev1/fvc \< 65% 9. unable to provide informed consent
reverse total shoulder arthroplasty versus open reduction internal fixation of 3&4 part proximal humerus fractures

Conditions: Closed Fracture Proximal Humerus, Four Part

Summary: will patients who suffer complex humerus fractures have better functional outcomes and less implant failure with shoulder replacement (reverse total shoulder arthroplasty, rtsa) compared to shoulder repair (open reduction and internal fixation, orif)?

the purpose of this study is to compare validated clinical and functional outcomes between patients who acutely present with 3 and 4-part proximal humerus fractures treated with either orif or rtsa.

Eligibility criteria:
inclusion * neer 3 and 4-part proximal humerus fractures. * age greater than and equal to 70 years old. * functional deltoid musculature (axillary nerve intact). exclusion * less than 70 years old. * dementia or inability to provide adequate follow up. * associated injuries: injuries of ipsilateral limb, complete brachial plexopathy, vascular injury and polytrauma.
study evaluating ima-638 in asthma

Conditions: Asthma

Summary: the purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of ima-638 in mild to moderate asthma subjects.


Eligibility criteria:
inclusion criteria: * men and women of non-childbearing potential with mild to moderate asthma as defined by forced expiratory volume in 1 second (fev1) greater than 70% predicted. * well controlled asthma, as exhibited by completion of asthma questionnaire. * otherwise healthy, except for asthma.

Keywords: healthy subjects
efficacy study of nucel® in patients undergoing fusion of the lumbar spine

Conditions: Intervertebral Disc Disease; Intervertebral Disc Degeneration; Spondylosis; Spondylolisthesis; Spinal Stenosis

Summary: the purpose of this study is to determine whether nucel is effective in promoting spinal fusion in degenerative disease of the lumbar spine.

the study is a prospective, single center clinical trial to establish the efficacy of nucel, a minimally manipulated allograft tissue, for use in lumbar interbody and intertransverse fusion procedures. subjects will undergo standard interbody fusion surgery as per the signed informed consent with nucel and autograft bone. patients will be evaluated postoperatively at 6 weeks, 3 months, 6 months, 1 year, and 2 years (if required).

Eligibility criteria:
inclusion criteria: * must be diagnosed with degenerative disease of lumbar spine exclusion criteria: * back pain due to injury * back pain that is caused by infection, cancer, lesions(growths) or bone disease such as osteoporosis * any terminal (will not recover from the disease) or autoimmune disease including but not limited to hiv infection, or rheumatoid arthritis * any other medical condition that might affect normal healing * less than 21 years of age * more than three levels of fusion needed * recent history (within past 6 months) of any chemical or alcohol dependence * morbid obesity (body mass index of more than 40) * currently a prisoner * currently experiencing a major mental illness * pregnancy at the time of enrollment * previously diagnosed with diseases of the bone such as osteoporosis, osteopenia or osteomalacia (softening of the bones). patients with any of the risk factors for osteoporosis may have dexa scans performed prior to study entry.

Keywords: nucel lumbar spine degenerative disease efficacy fusion
autoreactive anti-ro/ssa ige to determine primary sjögren's syndrome's disease activity

Conditions: Primary Sjögren's Syndrome

Summary: primary sjögren's syndrome (pss) can affect various organs, sometimes leads to life-threatening conditions and is always responsible for a decreased quality of life. its evolution is chronic, with flares and relapses, and the need for reliable biomarkers to be carried out routinely is major in patients' follow-up. because of the existence of autoreactive immunoglobulins e (ige) in autoimmune diseases, the recently described role for anti-ro/ssa antibodies in inducing interferon alpha (ifnα) signaling and the specific pharmacologic properties of ige, anti-ro/ssa ige should be an interesting biomarker to determine pss's activity. the aim of the study is to evaluate whether the proportion of anti-ro/ssa ige positive patients is higher in patients with active disease (i.e. eular sjögren syndrome disease activity index≥ 5). all consecutive patients with pss (new or already known diagnosis) will be included, anti-ro/ssa ige titers will be determined, the disease's features will be collected (including eular sjögren syndrome disease activity index/eular sjogren's syndrome patient reported index).


Eligibility criteria:
inclusion criteria: * primary sjögren's syndrome according to the american-european consensus criteria) * informed and having signed the study consent form exclusion criteria: * secondary sjögren's syndrome * other systemic autoimmune disease (e.g. rheumatoid arthritis, antineutrophil antibodies (anca) -associated vasculitis, mixed connective tissue disease...) * incapacity or refusal to sign the informed consent form * incapacity or refusal to perform the follow-up examinations required by the study * has received abatacept, sifalimumab, rontalizumab, anifrolumab, belimumab, tumor necrosis factor (tnf) antagonists or interferon during the 6 months prior to the inclusion * has any current signs or symptoms of active infection

Keywords: sjögren's syndrome immunoglobulin e anti-ro/ssa autoimmune disease biomarker
intermittent pneumatic compression of the upper extremity for post-operative vte prophylaxis

Conditions: Venous Thromboses

Summary: venous thromboembolism (vte) is an important cause of morbidity and mortality following surgery.a combination of chemical and mechanical prophylaxis using lower extremity compression devices (cd) is recommended in patients who are considered at 'moderate risk' (caprini score 2 - 4) or 'high risk' (caprini score \> 4) of developing vte. the aim of this study was to determine whether upper extremity (ue) cd are as effective as lower extremity (le) cd in preventing vte following surgery. a total of 106 patients were recruited.

hospitals throughout the united states currently utilize mechanical compression devices on patients' limbs for prevention of blood clots, in addition to blood thinning medication - heparin. the compression devices act by affect blood clotting mechanism and there is evidence from previous research studies that blood is less likely to develop clots when these compression devices are placed on the arms or legs. the use of compression devices on arms and legs is within standard of care, but use on legs tends to be more common. research studies have shown that use of compression devices in combination with heparin is more effective in preventing blood clots than either one alone. not many clinicians remember the option of placing compression devices on arms, and patients who do not get compression devices placed on their legs following surgery, often get only medication (heparin) with no compression device placed at all. this study will compare the effectiveness of compression devices used on patients' arms with those used on patients' legs, at preventing blood clots. non-invasive ultrasound studies will be used after surgery to check for blood clots in the legs.

Eligibility criteria:
inclusion criteria: • males aged \> 18 years who could provide informed consent exclusion criteria: * patients on coumadin or post-operative therapeutic heparin * known history of venous thromboembolism (vte) * known history of hematological disorders * diagnosed malignancy requiring or undergoing treatment * presence of upper extremity arterio-venous access for hemodialysis * females were excluded to eliminate the confounding thrombogenic effect of estrogen.
pulmicort respules(budesonide inhalation suspension) vs singulair, children

Conditions: Asthma

Summary: a one year study comparing the safety and effectiveness of pulmicort (0.5mg strength given once a day in the evening) with either 4 or 5mg strength singular (given once a day in the evening) in children with asthma aged 2 to 8. if allocated to singular treatment, children aged between 2 and 5 will receive 4mg strength singular and those aged between 6 and 8 will receive 5mg strength singular.


Eligibility criteria:
inclusion criteria: * aged 2 to 8 at study entry * at least 3 episodes of wheezing in the previous year that lasted more than 24 hours and affected sleep or symptoms of mild persistent asthma * use of b-2 agonist treatment on at least 3 of 7 consecutive days or run in exclusion criteria: * severe or unstable asthma * any significant finding at a physical exam * an exacerbation of asthma in the 30 days before entering the study that might affect study results in judgement of the study doctor

Keywords: asthma pulmicort children paediatrics budesonide
effect of myoinositol treatment of spermatozoa on in vitro fertilization outcome

Conditions: Couple Sterility

Summary: in the present trial, the investigators aim to evaluate whether semen myo-inositol (mi) treatment is able to improve ivf outcomes. in particular, retrieved oocytes will be randomly divided in two groups, one group will be inseminated with mi treated semen while the other will be inseminated with untreated semen.

myo is synthesized from glucose-6-phosphate, it is a precursor of second messengers in the cell signaling pathways and it is involved in the regulation of intracellular calcium. literature data have demonstrated the mi play a crucial role in reproduction, indeed, oocyte and spematozoa are nursed in a medium congaing hig mi concentration. furthermore, it has been demonstrated that, in oligoasthenoteratozoospermic patients, in vitro incubation with 2 mg/ml of myo increase significantly the number of spermatozoa with high mitochondrial membrane potential (mmp). moreover, it has been found that the in vitro fertilization rate is correlated with the percentage of high mmp spermatozoa.

Eligibility criteria:
inclusion criteria: * couple counselled for ivf exclusion criteria: * cryopreserved sample

Keywords: myoinositol art embryo quality
patient satisfaction with subdissociative dose ketamine versus morphine for emergency department pain control

Conditions: Abdominal Pain

Summary: the proposed research will be a single blinded (patient) randomized controlled prospective trial of adult patients receiving treatment for moderate to severe abdominal pain to test the hypothesis that patient satisfaction with pain control with ketamine will be comparable to patient satisfaction with pain control using morphine when treating abdominal pain.

informed consent will be obtained from patients presenting with chief complaint of moderate to severe abdominal pain in the emergency department who do not meet any exclusion criteria and who willingly agree to participate by signing the written consent form. investigators will assess the patient's opioid tolerance by asking if they have use an opioid medication in the last week, prescription opioid use at home, and/or recreational opioid use. patients in both groups will fill out the pre-treatment questionnaire, which will include demographic questions (age, sex, race, height, weight, etc.), a 10cm (100mm) vas for pain, a 10cm (100mm) vas to measure patient satisfaction, and a likert scale to measure patient satisfaction. post-treatment survey will be given at 30 minutes after administration of medication. the physician will record whether the patient required additional pain medication after the 30 minutes, final emergency department diagnosis, and final emergency department disposition.

Eligibility criteria:
inclusion criteria: * be at least 18 years of age * initial presenting complaint of moderate to severe abdominal pain (five or higher on numerical rating scale \[nrs\]). * subjects will be enrolled into the project one (1) time only. exclusion criteria: * under 18 years of age * pregnant patients * inability to provide written consent * evidence of traumatic brain injury * hemodynamic instability * procedures involving laryngeal manipulation * history of laryngeal spasm * history of adverse reaction to ketamine or morphine * patients will not be excluded if they had received pain medications prior to enrollment (ie. received pain medication from triage, non-physician provider (npp), or emergency medical services (ems) prior to being seen by physician * history of opioid use in the last week, prescription opioid use, recreational opioid use

Keywords: emergency department moderate to severe pain
18f-fdg uptake measurements in malignant solid tumors on pet/ct and pet/mr

Conditions: Solid Tumor, Adult

Summary: in the current study, the investigators plan to expand the knowledge of positron emission tomography/magnetic resonance (pet/mr) reliability by assessing the repeatability of fludeoxyglucose (fdg) standardized uptake values (suv) measurements, as well as apparent diffusion coefficients (adc) measurements, in a broad population of patients with malignant solid tumors.


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed malignant solid tumors (local or metastatic, newly diagnosed or recurrent disease). * patient must have at least one lesion measuring ≥ 2.0 cm. * 18 years of age or older. * ability to provide informed consent. exclusion criteria: * cancer therapy within 30 days of baseline imaging. * uncontrolled intercurrent illness including, but not limited to active infections. * patients with insulin-dependent diabetes. * patients with metal devices in the body including, but not limited to metallic joint prostheses, artificial heart valves, pacemakers, and cochlear implants. * patients who are pregnant or nursing. * inability to tolerate 60 minutes of pet imaging. * inability to comply with study procedures.
german lactat clearance in severe sepsis

Conditions: Severe Sepsis; Septic Shock

Summary: the aim of this study is to investigate if there is a correlation between lactate clearance and the course at patients with severe sepsis and septic shock at german intensive care units.


Eligibility criteria:
inclusion criteria: * patients with severe sepsis or septic shock * signed informed consent exclusion criteria: * severe sepsis or septic schock within 4 weeks before inclusion of study * shock of other genesis * persons being accomondated in an institution because of court or official order * persons being interdependet to the investigator * employees of the investigator